Latest Conference Articles

March 16th 2017, 5:38pm

St. Gallen International Breast Cancer Conference

C. Kent Osborne, MD, director, Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, discusses the death of chemotherapy and rise of targeted agents in the treatment of patients with HER2-positive breast cancer.

March 16th 2017, 12:51am

SGO Annual Meeting

An immunotherapy targeting HPV-infected cells led to an unprecedented 1-year survival rate in patients with recurrent, metastatic cervical cancer.

March 15th 2017, 11:27pm

SGO Annual Meeting

Maintenance chemotherapy after debulking surgery and adjuvant platinum-based chemotherapy did not improve overall survival rates in women with ovarian cancer who had achieved complete remission.

March 15th 2017, 2:26am

SGO Annual Meeting

Maintenance therapy with olaparib showed a 70% reduction in the risk of progression or death compared with placebo for patients with platinum-sensitive, relapsed, BRCA-mutant ovarian cancer.

March 15th 2017, 1:02am

SGO Annual Meeting

Christina M. Annunziata, MD, PhD, head, Translational Genomics Section, National Cancer Institute, discusses the phase II/III study of olaparib (Lynparza) and cediranib for patients with platinum-resistant ovarian cancer.

March 15th 2017, 12:50am

SGO Annual Meeting

Alon Altman, MD, associate professor, Department of Obstertrics, Gynecology and Reproductive Sciences, University of Manitoba, discusses neoadjuvant chemotherapy for patients with high-grade serous carcinoma.

March 14th 2017, 11:28pm

SGO Annual Meeting

Treatment with a carboplatin desensitization regimen led to improved overall survival in patients with BRCA-proficient ovarian cancer.

March 14th 2017, 11:13pm

SGO Annual Meeting

Mismatch repair-deficient endometrial cancers exhibited significantly higher levels of PD-L1 expression compared with MMR-intact tumors.

March 14th 2017, 5:47pm

SGO Annual Meeting

The PARP inhibitor niraparib improved progression-free survival in patients with recurrent, platinum-sensitive, high-grade ovarian cancer, regardless of BRCA status, according to a review of the phase III ENGOT-OV16/NOVA trial presented at the 2017 Society of Gynecologic Oncology Annual Meeting.

March 14th 2017, 2:43am

SGO Annual Meeting

Jubilee Brown, MD, obstetrician-gynecologist, Levine Cancer Institute, Carolinas HealthCare System, discusses genetic counseling for patients with breast and ovarian cancer.

March 14th 2017, 2:39am

SGO Annual Meeting

Ursula A. Matulonis, MD, professor of Medicine, Harvard Medical School, medical director of Gynecologic Oncology, Dana-Farber Cancer Institute, discusses the secondary efficacy results of the NOVA trial, which examines niraparib maintenance therapy for patients with ovarian cancer.

March 14th 2017, 2:23am

SGO Annual Meeting

A survey was given to parents of teenage girls in an effort to understand the relatively low uptake of the HPV vaccine in the United States.

March 13th 2017, 2:00pm

SGO Annual Meeting

Hypermethylation of 2 wild-type tumor-associated genes increased ovarian cancer responsiveness to the PARP inhibitor rucaparib (Rubraca).

March 13th 2017, 2:24am

SGO Annual Meeting

Lack of clinical coverage and time off topped the perceived hindrances to gynecologic oncologists’ participation in global health activities, according to a study reported at the Society of Gynecologic Oncology in National Harbor, MD.

March 13th 2017, 2:14am

SGO Annual Meeting

Emma Barber, MD, UNC Department of Obstetrics and Gynecology, UNC School of Medicine, UNC Lineberger Comprehensive Cancer Center, discusses surgical readmission and survival in patients with ovarian cancer.

March 13th 2017, 2:05am

SGO Annual Meeting

Elizabeth Swisher, MD, professor, Department of Medicine, Division of Medical Genetics, University of Washington School of Medicine, Breast and Ovarian Cancer Prevention Program, Seattle Cancer Care Alliance, discusses next steps regarding treatments for patients with ovarian cancer.

March 13th 2017, 12:15am

SGO Annual Meeting

The PARP inhibitor rucaparib slowed progression of relapsed BRCA-mutant ovarian cancer regardless of whether the mutations were somatic or germline, a new analysis of a phase II trial showed.

March 12th 2017, 2:03am

PER® Miami Breast Cancer Conference

For television personality, author, and lifestyle maven Sandra Lee the roots of her controversial decision to have a bilateral mastectomy go back to her childhood, when her grandmother was diagnosed with an advanced and aggressive form of stomach cancer.

March 12th 2017, 1:25am

PER® Miami Breast Cancer Conference

The success of olaparib in a phase III trial and recent data for other emerging agents has reversed the PARP narrative in breast cancer, Kimberly Blackwell, MD, said in a presentation at the 34th Annual Miami Breast Cancer Conference.

March 12th 2017, 1:17am

PER® Miami Breast Cancer Conference

Multiple ongoing clinical trials are evaluating various immunotherapy strategies for patients with breast cancer, with combinations representing the most potential for future success.